As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
8 Analysts have issued a Eyenovia, Inc. forecast:
8 Analysts have issued a Eyenovia, Inc. forecast:
| Mar '25 |
+/-
%
|
||
| Revenue | 0.07 0.07 |
600%
600%
|
|
| Gross Profit | -3.66 -3.66 |
-
|
|
| EBITDA | -30 -30 |
1%
1%
|
|
| EBIT (Operating Income) EBIT | -30 -30 |
0%
0%
|
|
| Net Profit | -42 -42 |
31%
31%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Michael Rowe |
| Employees | 14 |
| Founded | 2014 |
| Website | eyenovia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


